Stephens Investment Management Group LLC Increases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Stephens Investment Management Group LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 139,420 shares of the company’s stock after acquiring an additional 18,786 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Medpace were worth $46,320,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. R Squared Ltd purchased a new stake in Medpace during the 4th quarter worth approximately $30,000. Stone House Investment Management LLC purchased a new stake in shares of Medpace during the third quarter valued at $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $37,000. Capital Performance Advisors LLP purchased a new position in Medpace in the 3rd quarter worth $46,000. Finally, True Wealth Design LLC lifted its position in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research reports. TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Truist Financial dropped their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, Redburn Atlantic initiated coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Stock Down 1.9 %

NASDAQ:MEDP opened at $354.10 on Friday. The stock has a market capitalization of $11.01 billion, a PE ratio of 31.01, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock’s 50-day moving average price is $343.88 and its 200-day moving average price is $349.80.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.